We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$5.06B
AUM Growth
+$476M
Cap. Flow
+$367M
Cap. Flow %
7.25%
Top 10 Hldgs %
27.38%
Holding
165
New
14
Increased
67
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
AGL icon
Agilon Health
AGL
+$245M
2
LENZ
LENZ Therapeutics
LENZ
+$53.5M
3
NEUE
NeueHealth
NEUE
+$40.7M
4
VERV
Verve Therapeutics
VERV
+$40M
5
LFST icon
Lifestance Health
LFST
+$39.6M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$100M
2
AZN icon
AstraZeneca
AZN
+$32.3M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.2M
4
INSP icon
Inspire Medical Systems
INSP
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Consumer Staples 1.63%
3 Industrials 0.71%
4 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGL icon
1
Agilon Health
AGL
$1.55B
$284M 5.61%
+279,961
New +$245M
ZLAB icon
2
Zai Lab
ZLAB
$2.07B
$179M 3.55%
1,014,000
+80,500
+9% +$12.9M
AGIO icon
3
Agios Pharmaceuticals
AGIO
$2.08B
$142M 2.8%
2,574,308
+30,708
+1% +$1.72M
HUM icon
4
Humana
HUM
$43.9B
$134M 2.65%
302,500
+1,500
+0.5% +$655K
ALGN icon
5
Align Technology
ALGN
$12.9B
$115M 2.27%
187,750
+10,250
+6% +$6.07M
IDXX icon
6
Idexx Laboratories
IDXX
$44.9B
$114M 2.25%
180,000
– –
PODD icon
7
Insulet
PODD
$11.8B
$112M 2.22%
408,750
+37,750
+10% +$10.3M
ISRG icon
8
Intuitive Surgical
ISRG
$127B
$110M 2.18%
360,000
– –
NBIX icon
9
Neurocrine Biosciences
NBIX
$18.2B
$98.8M 1.95%
1,015,000
– –
NVAX icon
10
Novavax
NVAX
$1.21B
$96.6M 1.91%
455,000
-6,000
-1% -$1.1M
UNH icon
11
UnitedHealth
UNH
$382B
$96.1M 1.9%
240,000
-35,000
-13% -$14M
ARGX icon
12
argenx
ARGX
$55.2B
$94.8M 1.87%
315,000
+15,000
+5% +$4.27M
IMCR icon
13
Immunocore
IMCR
$1.7B
$93.5M 1.85%
2,394,785
+102,500
+4% +$3.96M
HCA icon
14
HCA Healthcare
HCA
$88.4B
$93M 1.84%
450,000
– –
NVRO
15
DELISTED
NEVRO CORP.
NVRO
$88M 1.74%
531,000
+46,000
+9% +$7.18M
FRPT icon
16
Freshpet
FRPT
$3.04B
$82.5M 1.63%
506,500
– –
NVTA
17
DELISTED
Invitae Corporation
NVTA
$77.6M 1.53%
2,302,032
+88,055
+4% +$2.86M
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$71.1M 1.41%
808,860
+62,128
+8% +$5.69M
EXAS
19
DELISTED
Exact Sciences
EXAS
$70.9M 1.4%
570,000
– –
ONC
20
BeOne Medicines Ltd
ONC
$33.9B
$68.6M 1.36%
200,000
– –
LENZ
21
LENZ Therapeutics
LENZ
$179M
$66.1M 1.31%
+307,391
New +$53.5M
ACRS icon
22
Aclaris Therapeutics
ACRS
$715M
$66.1M 1.31%
3,762,312
+193,120
+5% +$4.39M
PCRX icon
23
Pacira BioSciences
PCRX
$1.04B
$62.2M 1.23%
1,025,000
– –
EW icon
24
Edwards Lifesciences
EW
$49.4B
$60.3M 1.19%
582,000
– –
PHR icon
25
Phreesia
PHR
$689M
$58.8M 1.16%
960,000
+110,000
+13% +$5.73M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rock Springs Capital Management held 165 positions worth $5.06B, up 10% from $4.58B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $367M of net new capital in Q2 2021, opening 14 new positions and adding to 67 existing holdings. Its largest new stake was Agilon Health: 279,961 shares worth $284M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $27.2M trimmed.

  • Rock Springs Capital Management's largest Q2 2021 buy was Agilon Health: 279,961 shares worth $284M.
  • Rock Springs Capital Management added most to Eargo, Inc. Common Stock in Q2 2021, an estimated $25.1M increase.
  • Rock Springs Capital Management's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $27.2M.
  • Rock Springs Capital Management fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $100M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $5.06B portfolio in Q2 2021.
  • Rock Springs Capital Management opened 14 new positions and closed 9 in Q2 2021.
  • Rock Springs Capital Management's portfolio value rose 10% quarter-over-quarter to $5.06B.

Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.